Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887
Last $65.35 USD
Change Today +1.67 / 2.62%
Volume 14.4M
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $69.20
52 Week Low
06/5/14 - $46.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Request Investor Kit
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

AstraZeneca, Bristol-Myers Squibb: Intellectual Property
Bristol-Myers 2015 Sales Forecast Hit by Dollar’s Strength
Stronger Dollar Punishes U.S. Earnings From P&G to DuPont
Fed, U.S. GDP, Greece, Apple, Amazon: Week Ahead Jan. 24-31
Fed, U.S. GDP, Greek Vote, Apple, Amazon: Week Ahead Jan. 24-31

bristol-myers squibb co (BMY) Related News

Company News: Alstom, GE, American Apparel, Bristol-Myers Squibb, Airbus, Starbucks, Square
Prudential Piles on the Corporate Pensions
White-Collar Workers Live Longer and the Gap Is Widening
What's the Dollar Value of Online Patient Chatter?

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company Announces Transfer of Full Commercialisation Rights to Eli Lilly and Company for Erbitux (Cetuximab)

Bristol-Myers Squibb Company declared an agreement to transfer the rights to Erbitux (cetuximab) in North America, including the US, Canada and Puerto Rico, to Eli Lilly and Company. The companies added the rights include, but are not limited to, full commercialisation and manufacturing operational responsibilities of Erbitux (cetuximab), an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of patients with certain advanced colorectal and head and neck cancers. Following a 14-year collaboration, Lilly's wholly-owned subsidiary ImClone and Bristol-Myers Squibb will work closely to ensure a smooth transition on Erbitux. Bristol-Myers Squibb will receive tiered royalties based on net product sales in North America after the completion of the transition through September 2018. This transition is expected to be completed in the fourth quarter of 2015.

Bristol-Myers Squibb Company and uniQure Collaborate to Develop New Cardiovascular Disease Therapies

Bristol-Myers Squibb Company and uniQure N.V. have signed a new agreement, under which BMS receives access for uniQure's gene therapy technology platform to develop new therapies for cardiovascular diseases. The collaboration includes uniQure's proprietary gene therapy program for congestive heart failure that is intended to restore the heart's ability to synthesize S100A1, a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction. Beyond cardiovascular diseases, the agreement also includes the potential for target-exclusive collaboration in other disease areas. In total, the companies may collaborate on ten targets, including S100A1. uniQure will lead discovery efforts and be responsible for manufacturing of clinical and commercial supplies using its vector technologies and its industrial, proprietary insect-cell based manufacturing platform. Bristol-Myers Squibb will lead development and regulatory activities across all programs and be responsible for all R&D costs. Bristol-Myers Squibb will be solely responsible for commercialization of all products from the collaboration. This collaboration will accelerate the application of gene therapy for large patient populations suffering from heart diseases and will complement the further development of uniQure's internal pipeline in two focus areas: liver diseases, including hemophilia, and CNS, including lysosomal storage diseases.

Bristol-Myers Squibb Company, uniQure N.V. - Special Call

To discuss the collaboration with Bristol-Myers Squibb Company i.e. Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $65.35 USD +1.67

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $62.29 USD -0.30
Actavis plc $297.05 USD +0.60
Amgen Inc $163.58 USD -3.29
Medtronic PLC $76.49 USD -0.53
Novo Nordisk A/S kr376.90 DKK -5.50

Industry Analysis


Industry Average

Valuation BMY Industry Range
Price/Earnings 54.5x
Price/Sales 6.8x
Price/Book 7.3x
Price/Cash Flow 54.3x
TEV/Sales 5.9x

Sponsored Financial Commentaries

Sponsored Links

Overheard: Bristol-Myers Zigs While Market Zags
Bristol-Myers Zigs While Market Zags
With Bristol-Myers Trial Stopped Early, 'What's Next?'
Bristol-Myers Up Big After Drug Study Stopped Early
Bristol-Myers stops lung cancer trial after positive results
Bristol's Opdivo proves effective against second type of lung cancer
[Reuters] - A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against a common form of lung cancer, the company said, positioning the medicine for far ...
8:56 am Bristol-Myers announces that its CheckMate -057, a Pivotal Phase III Opdivo
CheckMate -057, a Pivotal Phase III Opdivo
[Business Wire] - Bristol-Myers Squibb Company today announced that an open-label, randomized Phase III study evaluating Opdivo versus docetaxel in previously treated patients with advanced non-squamous non-small cell lung cancer was stopped early because an assessment conducted by the independent Data Monitoring Committee concluded that the study met its endpoint, demonstrating superior overall survival in patients ...
How Bristol-Myers Squibb Makes the World Healthier
Bristol-Myers Squibb Completes Previously Announced Acquisition of Flexus Biosciences, Inc.
[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of Flexus Biosciences, Inc. ... This is an abstract ...